In the LUX-Lung 7 study, patients receiving first-line afatinib for EGFR mutant advanced NSCLC had significantly longer mPFS and median time-to-treatment failure than those on first-line gefitinib [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.